Nvest Financial LLC Sells 206 Shares of Danaher Co. (NYSE:DHR)

Nvest Financial LLC lessened its stake in shares of Danaher Co. (NYSE:DHR) by 6.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,205 shares of the conglomerate’s stock after selling 206 shares during the quarter. Nvest Financial LLC’s holdings in Danaher were worth $891,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Tsfg LLC boosted its holdings in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher during the second quarter valued at $25,000. nVerses Capital LLC purchased a new position in shares of Danaher during the 2nd quarter valued at about $25,000. Redmont Wealth Advisors LLC purchased a new stake in Danaher in the 1st quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. bought a new stake in Danaher during the 4th quarter worth approximately $42,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Up 1.5 %

NYSE DHR traded up $4.02 on Friday, hitting $270.47. 787,513 shares of the stock were exchanged, compared to its average volume of 2,722,173. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The firm has a market capitalization of $195.34 billion, a P/E ratio of 47.33, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a fifty day moving average price of $270.44 and a two-hundred day moving average price of $258.97.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.05 EPS. Research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 19.18%.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on DHR shares. Evercore ISI boosted their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Robert W. Baird upped their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen raised their target price on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, Bank of America boosted their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.